As drug pricing pressure intensifies and benefit structures shift, some health systems are still treating biosimilars as a selective cost lever — deploying them in certain payer segments while ...

The number of new prescriptions written for biosimilar versions of the Humira rheumatoid arthritis treatment, one of the best-selling medicines in the U.S., surged to 36% from just 5% during the first ...

Most shoppers are familiar with CVS Health’sCVS-1.09%decrease; red down pointing triangle many private-label products, from women’s daily multivitamins to heart-healthy trail mix. There is a reason ...

Biologic copycats are making a bigger impact on drug prices as U.S. regulators open the doors wider, and new guidance could ...

In the U.S., Alvotech’s biosimilar to Johnson & Johnson's blockbuster immunology drug Stelara is set to face market competition from the likes of Amgen, Sandoz and Fresenius Kabi. But elsewhere, ...

The NCCN guidance transitioned from a specific focus on rituximab to a broad, future-proof policy covering all FDA-approved biosimilars, which simplifies treatment decisions and promotes patient ...

CVS Health Inc. CVS on Thursday said it is taking additional steps to lower prescription drug costs by expanding access to biosimilar medications, announcing new formulary changes that will take ...

LAS VEGAS—Biosimilars hold significant promise in reducing pharmacy costs, and pharmacy benefit managers have touted them for years as being the key to introducing competition to some of the most ...

Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and ...

With its biosimilars business thriving, Amgen is in a unique position to comment on U.S. biosimilar policy as the current administration introduces reforms to increase the availability of the copycat ...